SQZB (SQZ Biotechnologies Co) Return-on-Tangible-Equity: -715.85% (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SQZB SQZ Biotechnologies Co SQZB
12 GF Score
Price $0.02
View Full Analysis

What is SQZ Biotechnologies Co Return-on-Tangible-Equity?

SQZ Biotechnologies Co SQZB 12 Return-on-Tangible-Equity is -715.85% as of Sep. 2023. GuruFocus rates SQZB with a GF Score™ of 12/100.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SQZ Biotechnologies Co's annualized net income for the quarter that ended in Sep. 2023 was $-94.56 Mil. SQZ Biotechnologies Co's average shareholder tangible equity for the quarter that ended in Sep. 2023 was $13.21 Mil. Therefore, SQZ Biotechnologies Co's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2023 was -715.85%.

The historical rank and industry rank for SQZ Biotechnologies Co's Return-on-Tangible-Equity or its related term are showing as below:

SQZB's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.4
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

SQZ Biotechnologies Co  (OTCPK:SQZB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


SQZ Biotechnologies Co Return-on-Tangible-Equity Related Terms


SQZ Biotechnologies Co Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for SQZ Biotechnologies Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SQZ Biotechnologies Co Return-on-Tangible-Equity Chart

SQZ Biotechnologies Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
0.00 0.00 -188.22 -54.74 -87.75

SQZ Biotechnologies Co Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.55 -86.20 -145.42 -207.38 -715.85

SQZB vs AGTX, ISCO, VYNT: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, SQZ Biotechnologies Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQZ Biotechnologies Co Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's Return-on-Tangible-Equity falls into.


SQZB
12GF Score
SQZ Biotechnologies Co SQZB
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SQZ Biotechnologies Co Return-on-Tangible-Equity Calculation

SQZ Biotechnologies Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-79.464/( (123.976+57.148 )/ 2 )
=-79.464/90.562
=-87.75 %

SQZ Biotechnologies Co's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-94.556/( (24.537+1.881)/ 2 )
=-94.556/13.209
=-715.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -715.85% mean?
SQZ Biotechnologies Co (SQZB) has a Return-on-Tangible-Equity of -715.85% as of Sep. 2023. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SQZ Biotechnologies Co and its competitors.
Is SQZ Biotechnologies Co's Return-on-Tangible-Equity too high?
SQZ Biotechnologies Co's current Return-on-Tangible-Equity is -715.85%. Overall, SQZ Biotechnologies Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SQZ Biotechnologies Co's Return-on-Tangible-Equity compare to AGTX and ISCO?
SQZ Biotechnologies Co's Return-on-Tangible-Equity of -715.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SQZ Biotechnologies Co and its competitors. SQZ Biotechnologies Co's current Return-on-Tangible-Equity is -715.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SQZ Biotechnologies Co stock overvalued right now?
SQZ Biotechnologies Co (SQZB) has a current Return-on-Tangible-Equity of -715.85%. The current Return-on-Tangible-Equity is -715.85%. SQZ Biotechnologies Co's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SQZ Biotechnologies Co (SQZB), the current Return-on-Tangible-Equity is -715.85% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SQZ Biotechnologies Co Business Description

Address 200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
12GF Score

Get the complete analysis for SQZB

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price